網膜静脈分枝閉塞症に伴う黄斑浮腫に対する硝子体手術あるいはベバシズマブ硝子体内注入の効果

Outcome of branch retinal vein occlusion with macular edema following vitreous surgery or intravitreal bevacizumab

要約　目的：黄斑浮腫を伴う網膜静脈分枝閉塞症に対し，硝子体手術またはベバシズマブ硝子体内注入を行った結果の比較。対象と方法：過去53か月間に治療した黄斑浮腫を伴う網膜静脈分枝閉塞症27例27眼を対象とした。最初の33か月間の12眼には硝子体手術を行い，それ以後の15眼にはベバシズマブの硝子体内注入を行った。結果：術前視力と比較し，硝子体手術群では1か月後に変化がなく，3か月後に改善し，以後12か月後まで維持した。ベバシズマブ群では1か月後に有意に改善し，3か月以降では有意差がなかった。結論：黄斑浮腫を伴う網膜静脈分枝閉塞症では，硝子体手術後には視力が緩やかに改善し，12か月後も維持される。ベバシズマブ硝子体内注入後には視力が速やかに改善するが，効果は持続しない。

Abstract.　Purpose：To compare the visual outcome of branch retinal vein occlusion（BRVO）with macular edema following vitreous surgery or intravitreal bevacizumab. Cases and Method：This study was made on 27 eyes of 27 patients of BRVO with macular edema seen during the past 53 months. Vitreous surgery was performed on 12 eyes during the initial 33 months. Bevacizumab was intravitreally injected in 15 eyes during the latter period. Results：In vitreous surgery group,visual acuity remained the same as that before surgery after one month,improved after 3 months to remain up to 12 months. In bevacizumab group,visual acuity improved after one month and showed no difference after 3 months when compared with the value before treatment. Conclusion：Visual acuity in eyes with BRVO with macular edema improved gradually until 12 months following vitreous surgery. It improved one month following intravitreal bevacizumab and returned to the pretreatment level after 3 months.